Michele Merli

scuola frequentata: Università di Pavia

occupazione: ricercatore

Serie

There is nothing here

Crea una nuova serie

Opere

There is nothing here

Crea un nuovo lavoro

Articoli 55

Data

Titolo

Autori

2020-04-28

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

Michele Merli, Francesco Passamonti, Luca Arcaini
2020-06-11

Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection

Michele Merli
2020-06-15

Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi

Michele Merli, Emanuele Cencini
2020-08-11

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

Marzia Varettoni, Francesco Piazza, Michele Merli, Giulia Benevolo, Massimo Gentile, Luca Arcaini
2020-10-13

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

Elisa Rumi, Michele Merli, Laura Libera, Daniela Pietra, Francesco Passamonti
2020-11-05

Direct-acting Antivirals in Hepatitis C Virus-positive Mantle Cell Lymphomas

Michele Merli, Emanuele Cencini, Sara Rattotti, Francesco Passamonti
2019-11-01

Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study

Michele Merli
2019-11-01

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Barbara Mora, Paola Guglielmelli, Elisa Rumi, Rami S Komrokji, Jean-Jacques Kiladjian, Alessandra Iurlo, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Francesco Albano, Giulia Benevolo, Silvia Uccella, Michele Merli, Tiziano Barbui, Mario Cazzola, Alessandro Maria Vannucchi, Francesco Passamonti, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella
2019-11-07

A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!

Michele Merli, Francesco Passamonti
2019-02-11

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Michele Merli, Pier Luigi Zinzani, Kirit M. Ardeshna
2019-07-10

Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study

Stefano Luminari, Michele Merli, Vittoria Tarantino, Marzia Varettoni, Carlo Visco, Simone Ferrero, Ombretta Annibali, Marco Frigeni, Luca Arcaini, Michele Spina
2019-12-13

Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Marco Frigeni, Carlo Visco, Michele Merli, Massimo Gentile, Luca Arcaini
2019-09-09

Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network

Marzia Varettoni, Emanuela Boveri, Silvia Zibellini, Michele Merli, Sara Rattotti, Marco Paulli, Luca Arcaini
2018-04-05

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project

Francesco Albano, Jean-Jacques Kiladjian, Michele Merli, Daniela Pietra
2018-06-06

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Maciej Lalowski, Leonardo Campiotti, Alessandro Morotti, Rocco Piazza, Vera Magistroni, Sara Redaelli, Luca Massimino, Marco Peronaci, Alicia Rubio, Fabio Stagno, Michele Merli
2018-05-04

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

Beatrice Casadei, Simone Ferrero, Michele Merli, Livio Trentin, Lisa Argnani, Pier Luigi Zinzani, Rossella Paolini
2018-09-21

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

Paola Guglielmelli, Valerio De Stefano, Francesco Albano, Daniela Pietra, Alessandro Rambaldi, Michele Merli, Toni Giorgino
2018-11-08

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study

Emilio Iannitto, Corinne Haioun, Claudio Tripodo, L Baseggio, Simonetta Zupo, Michele Merli, Benoît Tessoulin, Aurore Perrot, Alexandra Traverse-Glehen, Catherine Thieblemont
2018-11-08

Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death

Carlo Visco, Annalisa Chiappella, Simone Ferrero, Michele Merli, Francesco Piazza, Eva Hoster
2018-12-14

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas

Michele Merli, Marco Frigeni, Caroline Besson, Francesco Piazza, Paolo Grossi, Luca Arcaini
2017-01-31

Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma

Michele Merli
2017-02-15

Antiviral therapies for managing viral hepatitis in lymphoma patients

Michele Merli, Luca Arcaini
2017-04-05

Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus-positive diffuse large B-cell lymphomas

Michele Merli, Marco Frigeni, Paolo Grossi, Raffaele Bruno, Luca Arcaini
2017-08-03

Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.

Carmelo Carlo-Stella, Francesco Gaudio, Michele Merli, Giuseppe Gritti, Livio Trentin, Maurizio Bonfichi, Michele Spina, Lisa Argnani, Pier Luigi Zinzani, Amalia De Renzo, Vittorio Stefoni, Cinzia Pellegrini
2017-05-23

Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.

Armando Santoro, Paolo Corradini, Francesco Gaudio, Michele Merli, Maurizio Bonfichi, Michele Spina, Lisa Argnani, Pier Luigi Zinzani, Amalia De Renzo, Alessandro Pulsoni, Vittorio Stefoni, Cinzia Pellegrini
2017-05-31

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Paola Guglielmelli, Francesco Albano, Daniela Pietra, Toni Giorgino, Alessandro Rambaldi, Jean-Jacques Kiladjian, Francesca Palandri, Michele Merli
2016-10-01

Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma

Michele Merli, Luca Arcaini
2016-09-07

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Olivier Hermine, Luca Arcaini, Caroline Besson, Marco Frigeni, Hélène Fontaine, Milvia Casato, Marcella Visentini, Harrys A Torres, Véronique Loustaud-Ratti, Roberto Rossotti, Francesco Zaja, Sara Rattotti, Raffaele Bruno, Michele Merli, Laurent Alric, Stanislas Pol, Fabrice Carrat, Virginia Ferretti, Carlo Visco
2016-07-14

New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma

Michele Merli, Luca Arcaini, Francesco Passamonti, Margherita Maffioli
2016-02-17

Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program

Paolo Corradini, Pier Luigi Zinzani, Emanuele Angelucci, M Christina Cox, Attilio Guarini, Michele Merli, Lisa Argnani
2016-11-25

Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients

Paola Guglielmelli, Francesco Albano, Daniela Pietra, Jean-Jacques Kiladjian, Francesca Palandri, Michele Merli
2015-01-01

Everolimus in diffuse large B-cell lymphomas

Michele Merli, Luca Arcaini, Francesco Passamonti, Margherita Maffioli

Human - wd:Q60449061

Benvenuto su Inventaire

la biblioteca dei tuoi amici e della tua comunità

ulteriori informazioni